tti-101
·Code: TTI-101
tti-101: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | Phase 2 |
Clinical Trials (1)
REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Frequently asked questions
Who is developing tti-101?
tti-101 is being developed by Tvardi Therapeutics, Inc..
How many clinical trials involve tti-101?
BioSniper tracks 1 clinical trial involving tti-101.
Get deeper analysis on tti-101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis